Drug intelligence / Profile preview

DXL702

Development stage: Preclinical
Lead developer: InNexus Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

DXL702 is an experimental anti-HER2 monoclonal antibody developed using InNexus Biotechnology’s Dynamic Cross Linking (DXL) technology platform to enhance antibody binding affinity and antitumor potency against HER2-positive cancers. Preclinical xenograft studies in HER2-positive breast cancer models demonstrated superior tumor growth inhibition for DXL702 compared with trastuzumab, supporting its potential as a targeted therapy for HER2-overexpressing tumors.[8][14]

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on DXL702.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DXL702.

Explore the full profile